PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.

@article{Ho2012PDGFRA,
  title={PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.},
  author={Alan Loh Ho and Shyamprasad Deraje Vasudeva and Marick La{\'e} and Tsuyoshi Saito and Violetta Barbashina and Cristina R Antonescu and Marc Ladanyi and Gary K. Schwartz},
  journal={Cancer research},
  year={2012},
  volume={72 17},
  pages={4515-25}
}
Akt activation by the IGF-1 receptor (IGF-1R) has been posited to be a mechanism of intrinsic resistance to mTORC1 inhibitors (rapalogues) for sarcomas. Here we show that rapamycin-induced phosphorylation of Akt can occur in an IGF-1R-independent manner. Analysis of synovial sarcoma cell lines showed that either IGF-1R or the PDGF receptor alpha (PDGFRA) can mediate intrinsic resistance to rapamycin. Repressing expression of PDGFRA or inhibiting its kinase activity in synovial sarcoma cells… CONTINUE READING
19 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors

  • S Di Cosimo, J Bendell, A Cervantes-Ruiperez, D Roda, L Prudkin, M Stein
  • ASCO Meeting Abtr 2010;28
  • 2010
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…